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ISSNObjective: To estimate the cost-effectiveness of prevention of mother-to-child trans-
mission (MTCT) of HIV with lifelong antiretroviral therapy (ART) for pregnant and
breastfeeding women (‘Option Bþ’) compared with ART during pregnancy or breast-
feeding only unless clinically indicated (‘Option B’).
Design: Mathematical modelling study of first and second pregnancy, informed by data
from the Malawi Option Bþ programme.
Methods: Individual-based simulation model. We simulated cohorts of 10 000 women
and their infants during two subsequent pregnancies, including the breastfeeding
period, with either Option Bþ or B. We parameterized the model with data from
the literature and by analysing programmatic data. We compared total costs of antenatal
and postnatal care, and lifetime costs and disability-adjusted life-years of the infected
infants between Option Bþ and Option B.
Results: During the first pregnancy, 15% of the infants born to HIV-infected mothers
acquired the infection. With Option Bþ, 39% of the women were on ART at the
beginning of the second pregnancy, compared with 18% with Option B. For second
pregnancies, the rates MTCT were 11.3% with Option Bþ and 12.3% with Option B.
The incremental cost-effectiveness ratio comparing the two options ranged between
about US$ 500 and US$ 1300 per DALY averted.
Conclusion: Option Bþ prevents more vertical transmissions of HIV than Option B,
mainly because more women are already on ART at the beginning of the next
pregnancy. Option Bþ is a cost-effective strategy for PMTCT if the total future costs
and lost lifetime of the infected infants are taken into account.
Copyright  2016 Wolters Kluwer Health, Inc. All rights reserved.AIDS 2016, 29:953–961Keywords: antiretroviral therapy, cost-effectiveness, mathematical modelling,
prevention of mother-to-child transmission Option BþIntroduction
About 240 000 children acquired HIV from their mothers
in 2013 [1]. In the absence of preventive interventions,
the risk of mother-to-child transmission of HIV (MTCT) Copyright © 2016 Wolters Kluwe
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954 AIDS 2016, Vol 30 No 6In 2011, Malawi was the first country to introduce a
prevention of mother-to-child transmission (PMTCT)
programme known as ‘Option Bþ’: all HIV-infected
pregnant and breastfeeding women start lifelong ART
regardless of their CD4þ cell count or HIV clinical stage.
Infants receive daily nevirapine over 6 weeks [6]. Since
2013, Option Bþ has been recommended by the WHO
as one of two PMTCT strategies. The alternative strategy,
‘Option B’, recommends ART only for the duration of
pregnancy or breastfeeding, unless women qualify for
ART for their own health [7].
Option Bþ has potential advantages over Option B for
mothers, infants and programme delivery. Most studies
evaluating the benefits of Option Bþ have only
considered the clinical benefits to the mother through
early initiation of lifelong ART [8,9]. However, Option
Bþ may also prevent more MTCT than Option B. In
Malawi, the fertility rate is high (5.5 births per woman)
[10], and many women breastfeed for 2 years or longer
[11]. With Option Bþ, most HIV-infected women are
already on ART when they become pregnant the next
time, whereas with Option B they need to restart therapy.
We estimated the risk of MTCTwith Options Bþ and B
in two subsequent pregnancies, and compared their cost-
effectiveness.Materials and methods
Mathematical model
We developed a mathematical model for MTCTof HIV
that simulates the progression of HIV infection. The
progression of individuals across healthcare interventions
and stages of the disease is represented by a sequence of
states and transitions. Transition times are sampled from
time-to-event distributions. We used the R package
‘gems’ [12] which is described in detail elsewhere [13].
Supplementary Text S1, http://links.lww.com/QAD/
A862, details the implementation of the model in gems.
We simulated cohorts of 10 000 primigravida, used the
results to simulate their infants from conception to 2 years
after delivery and, finally, updated mothers’ simulation
based on the infants’ simulation. In Malawi about 98% of
women who survive their first pregnancy become
pregnant with a second child [10,14]. We sampled 98%
of surviving women and repeated the procedure,
modelling the mother and her second infant. The model
was parameterized with data from a recent analysis of
retention in care under Option Bþ in Malawi [15],
relevant literature on HIV incidence rates of miscarriage,
stillbirth and mortality, MTCT, information on demo-
graphic characteristics, HIV testing, access to antenatal
(ANC) and postnatal care, [16–22], and national HIV
prevalence data from Malawi Ministry of Health [23,24]
(Table 1; supplementary Table S1, http://links.lww.com/ Copyright © 2016 Wolters Kluwer HQAD/A862). For the main analysis, we simulated
200 cohorts, and present the mean over all cohorts
as well as the 95% prediction interval (6th and 195th value
of the individual cohorts, ordered from smallest to
greatest). The results for a cohort of 10 000 women are
expected to lie within this interval with a 95% probability.
For secondary analyses, we ran 10 cohorts, and report
the means.
Simulation of pregnant and breastfeeding women
The model consisted of 58 states (Fig. 1, supplementary
Table S2, http://links.lww.com/QAD/A862). The
simulation starts at conception with each woman
proceeding through the stages of pregnancy, delivery
and breastfeeding, of HIV infection, and ANC and
postnatal care. Women may either be HIV negative, or at
an early stage of HIV infection (HIV infection within last
5 years) at the first conception. We did not include
women who were at a late stage of HIV infection, or who
started ART before the first conception, because the
outcomes for these women would not differ between
Option Bþ and Option B. Women were either in ANC
or postnatal care, or out of care if they did not seek care or
were lost to follow-up, and could die at any stage.
Simulation of infants
The model included 21 states, representing the devel-
opment (fetus/infant), HIV status and ART status
(supplementary Table S3, http://links.lww.com/QAD/
A862, and supplementary Figure S1, http://links.lww.
com/QAD/A862). The simulation starts with an HIV-
uninfected fetus that becomes at risk of HIV infection if
the mother is HIV positive. The risk of MTCT depends
on the stage (pregnancy, delivery or postnatal), type of
breastfeeding (exclusive or mixed), phase of mother’s
HIV infection (acute or chronic) and the mother’s
treatment (ARTor no ART). A child receives HIV tests,
nevirapine, cotrimoxazole prophylaxis and, if necessary,
ART, according to the national guidelines, as long as the
mother is alive and in care [25].
Prevention of mother-to-child transmission
strategies
We modelled Option Bþ, Option B and a third scenario
wherein no PMTCT services or ART were provided.
In the Option B/Bþ scenarios, ART was offered to all
HIV-positive women in care. In Option B, ART was
discontinued after stopping breastfeeding, except for
women who were eligible for ART based on their clinical
or immunological status at ART initiation. In Option
Bþ, we calculated the cumulative risk of loss to follow-up
(LTFU) up to the second pregnancy, to estimate the
number of women who were on ARTat the beginning of
the second pregnancy. In addition to ART, PMTCT
services included HIV testing and counselling for
pregnant and breastfeeding women attending ANC or
postnatal care, and antiretroviral prophylaxis for infantsealth, Inc. All rights reserved.
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Table 1. Selected input parameters for the mathematical model of scenarios to prevent mother-to-child transmission of HIV in Malawi.
Variable Value Data source
Baseline characteristics
Age [mean (SD), in years] 19.5 (3.1) National antenatal data (unpublished
data)
HIV prevalence in pregnant women at the beginning of
first pregnancy
7.6% [24]
Rate of access to ANC services for first pregnancy (per person-year)
Within first trimester of pregnancy 0.38 [24]
Within second trimester of pregnancy 7.2 [24], National antenatal data
(unpublished data)
After 6 months of pregnancy 5.7 [24], National antenatal data
(unpublished data)
HIV incidence (per person-year)
During pregnancy 0.047 [16]
Postpartum 0.029 [16]
LTFU in antenatal care
Probability of no follow-up visit after ART initiation 16.4% [15]
Rate of LTFU (per person-year) 0.245 [15]
LTFU in postnatal care
Probability of no follow-up visit after ART initiation 8.9% [15]
Rate of LTFU with exclusive breastfeeding (per person-
year)
0.131 [15]
Hazard ratio of LTFU during mixed breastfeeding
compared with exclusive breastfeeding
1.5 Assumption
HIV testing
Probability of HIV test at ANC first visit 81% [24], National antenatal data
(unpublished data)
Cumulative probability of HIV test after first ANC visit, if
no test at first visit
11% [24], National antenatal data
(unpublished data)
Rate during postnatal care if no test before 5 Assumption
HIV transmission during pregnancy and delivery
In chronic stage without ART: Weibull scale 0.7 See section 2.3, supplementary Text S1,
http://links.lww.com/QAD/A862
In chronic stage without ART: Weibull shape 4.2 See section 2.3, supplementary Text S1,
http://links.lww.com/QAD/A862
In acute stage (hazard ratio compared with chronic stage) 6 [17]
On ART (hazard ratio compared with no ART) 0.04 [17]
HIV transmission from mother to child during breastfeeding
During first 3 months of exclusive breastfeeding without
ART (rate per person-year)
0.35 [18]
After first 3 months exclusive breastfeeding without ART
(rate, after 3 months)
0.09 [19]
In acute stage (hazard ratio compared with chronic stage) 6 [20]
On ART (hazard ratio compared with no ART) 0.04 [21]
During mixed breastfeeding (hazard ratio compared with
exclusive breastfeeding)
2.9 [22]
ANC, antenatal care; ART, antiretroviral therapy; LTFU, loss to follow-up.born to HIV-infected women. Overall 93% of the HIV-
infected women started ART [23].
Outcomes
The main outcome was MTCT of HIV (the proportion
of infants born to HIV-infected mothers who acquired the
infection). We also calculated the proportions of women
who were HIV positive at the beginning and at the end of
the first and second pregnancy, the proportion of women
who attended ANC or postnatal care, and the proportions
of HIV-positive women who started ART, and who were
on ART at the beginning of the second pregnancy.
Cost-effectiveness analysis
We compared Option Bþ with Option B. We included
the costs (in US$) of PMTCT services (including HIV
tests, consultations and ARVs), and the costs of CD4þ cell Copyright © 2016 Wolters Kluwecounts to determine eligibility for lifelong ART under
Option B. For HIV-exposed infants, we itemized the
costs of early infant diagnosis (6 weeks after birth), rapid
HIV tests (12 and 24 months after birth), ARV
prophylaxis and cotrimoxazole prophylaxis (supple-
mentary Table S4, http://links.lww.com/QAD/A862).
For future costs of treatment of the infected infants, we
considered a range between US$ 50 and US$ 300 per
year. We estimated the total disability-adjusted life years
(DALYs) and total costs for managing the HIV-infected
infants. We assumed that the life expectancy of an
uninfected infant would be 60 years [26], but 2 years for
an untreated infant infected during pregnancy or delivery,
and 10 years for an infant infected during breastfeeding.
For the life expectancy of treated infected infants, we
considered a range between 20 and 60 years. We assumed
that all infants who started ART remain on ART for ther Health, Inc. All rights reserved.
956 AIDS 2016, Vol 30 No 6rest of their life. We applied a constant disability weight
of 0.135 for all untreated HIV-infected infants,
which accounts for HIV and related conditions [27].
We calculated the incremental cost-effectiveness ratio
(ICER) between the two scenarios, defined as the
additional cost per DALY averted. All costs and DALYs
were discounted annually by 3%.Sensitivity analyses
We performed sensitivity analyses to explore the effect of
key model parameters. Retention in care among women
who start ART for PMTCT is lower than in general ART
programmes [28]. We explored how improved retention
would affect MTCT in Options Bþ and B. First, we
reduced LTFU from ANC and postnatal care by 75%.
Second, we increased the 1-year retention in care among
women who started ART based on Option Bþ and were
not clinically eligible for ART from 80% to 90%. Third,
we conducted a best-case scenario wherein we increased
the rates of attending ANC to 99% (20% of women
attending during the first trimester) and HIV testing
probability to 96%, and decreased the rates of LTFU by
75%. We also conducted a cost-effectiveness analysis
where two scenarios of both Option Bþ and Option B
were included (one using the parameters of the main
analysis, and one from this ‘best-case’ sensitivity analysis).
Finally, we conducted a sensitivity analysis where we
applied a lower HIV incidence rate, based on an estimate
from West Africa (0.7 per 100 person-years) [16].Results
Among women who attended ANC, about 95% received
an HIV test during the first pregnancy (Fig. 2, Copyright © 2016 Wolters Kluwer H
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Fig. 1. Schematic representation of the mathematical simulation m
across the stages of HIV status, pregnancy/breastfeeding and HIV/supplementary Table S5, http://links.lww.com/QAD/
A862). The proportion of women receiving an HIV test
was lower in the second pregnancy: 89% with Option
Bþ and 92% with Option B. About 16% of women were
infected with HIV at the end of the first pregnancy, with
about half of them having been infected before
conception of the second pregnancy. At the end of the
second pregnancy 23% of women were infected. About
43% of the women who were HIV positive at the end of
the first simulation, had started ART by 2 years after
delivery. With Option Bþ, 68% of the HIV-positive
women received ART during the second pregnancy: 39%
of the infected women were already on ART at the
beginning of the second pregnancy. For Option B, the
corresponding percentages were lower: 66 and 18%,
respectively.
About 190 (15%) of around 1270 infants born to HIV-
positive mothers (including both mothers who started
and who did not start ART) were HIV-infected by
24 months after the first pregnancy (Fig. 2). The risk of
HIV transmission was lower among women who started
ART during pregnancy or breastfeeding (around 13%).
After the second pregnancy 202 (11.3%) of 1783 infants
born to HIV-positive mothers were infected by 24 months
with Option Bþ, compared with 219 (12.3%) of 1782
with Option B. Among women who started ART at the
first ANC visit or were already on ART, the risk
of transmission was 8.6% (first pregnancy), 6.8% (second
pregnancy, Option Bþ) or 7.8% (second pregnancy,
Option B).
In the scenario with no PMTCTor ART, 22.0 and 29.3%
of infants born to infected mothers were infected after 24
months in the first and second pregnancies, respectively
(supplementary Table S6, http://links.lww.com/QAD/
A862).ealth, Inc. All rights reserved.
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Option B+ Option B
1st pregnancy
10 000 women
759 infected at start of pregnancy
1st pregnancy
10 000 women
757 infected at start of pregnancy
8421 attend  ANC
7959 are tested for HIV
674 start ART during pregnancy
8423 attend  ANC
7961 are tested for HIV
674 start ART during pregnancy
Outcomes
7951 live births
1273 HIV exposed infants
136 (10.7%) infants HIV infected by 6 weeks
Outcomes
7954 live births
1272 HIV exposed infants
138 (10.9%) infants HIV infected by 6 weeks
At 2 years after delivery
1575 women are HIV postive
213 infants died
187 (14.7%) infants are HIV positive
At 2 years after delivery
1573 women are HIV postive
215 infants died
189 (14.9%) infants are HIV positive
2nd pregnancy
9715 women
1510 infected at start of pregnancy
581 on ART
2nd pregnancy
9716 women
1507 infected at start of pregnancy
278 on ART
8821 attend ANC
7812 are tested for HIV
846 start ART during pregnancy
8784 attend ANC
8084 are tested for HIV
1089 start ART during pregnancy
Outcomes
7703 live births
1783 HIV exposed infants
156 (8.8%) infants HIV infected by 6 weeks
Outcomes
7704 live births
1782 HIV exposed infants
170 (9.5%)  infants HIV infected by 6 weeks
At 2 years after delivery
2229 women are HIV positive
209 infants died
202 (11.3%) infants are HIV positive 
At 2 years after delivery
2228 women are HIV positive
213 infants died
202 (12.3%) infants are HIV positive 
Fig. 2. Main outcomes of the model in Option BR and Option B prevention of mother-to-child transmission strategies.
Differences between Option Bþ and Option B during the first pregnancy are because of random variation.Cost-effectiveness
Figure 3 shows the cost-effectiveness of Option Bþ
compared with Option B for the cohort of 10 000
women with a first pregnancy, as a function of the annual
costs of HIV care and the life expectancy of the treated
HIV-infected infants. Assuming that the annual cost is
US$ 193.60 (the current price of first-line ART) and the
treated HIV-infected infants live for 50 years, the total
costs for PMTCT in the first pregnancy for Option Bþ
and Option B were US$ 431 910 and US$ 366 109,
respectively (supplementary Table S7, http://links.lww. Copyright © 2016 Wolters Kluwecom/QAD/A862). During the second pregnancy, the
costs were US$ 662 074 (Option Bþ) and US$ 564 549
(Option B). The cost of averting one HIV infection by
Option Bþwas US$ 13 880. We estimated that under the
assumptions on life expectancy and future HIV care costs
mentioned above, lifelong HIV services for the infants
from the second pregnancies would cost US$ 313 095
(Option Bþ) or US$ 364 512 (Option B). The total
number of DALYs in the infected infants under these
assumptions for the second pregnancy were 3109 (Option
Bþ) and 3240 (Option B), and the ICER of Option Bþr Health, Inc. All rights reserved.
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Fig. 3. Cost-effectiveness of Option BR compared with Option B for preventing mother-to-child transmission. The colour
represents the incremental cost-effectiveness ratio, depending on the assumed life expectancy of vertically infected infants who
receive treatment (vertical axis), and the assumed annual cost of HIV care in the future (horizontal axis). ICER, incremental cost-
effectiveness ratio; DALY, disability-adjusted life year.compared with Option B was US$ 841 per DALYaverted.
The cost-effectiveness improved with decreasing life
expectancy of the treated infants, and with increasing
annual costs of HIV care. With a life expectancy of
20 years for the treated infants and annual HIV care cost of
US$ 300, the ICER was less than US$ 500 per DALY
averted. With a life expectancy of 60 years for the treated
infants and annual HIV care cost of US$ 50, the ICER
was over US$ 1300 per DALY averted.
Sensitivity analyses
When LTFU was reduced by 75% during ANC and
postnatal services, the risk of MTCT for the second infant
was 10.6% in Option B, and 9.0% in Option Bþ
(supplementary Table S8, http://links.lww.com/QAD/
A862). The ICER was US$ 2316 per DALY averted,
assuming 50-year life expectancy for infected and treated
infants, and annual cost of US$ 193.60 per year. Improved
retention between the end of breastfeeding of the first
infant and the beginning of the second pregnancy did not
influence the risk of MTCT (supplementary Table S8,
http://links.lww.com/QAD/A862). In the best-case
scenario, the risk of MTCT was 9.1% with Option Bþ
and 9.6% with Option B (Fig. 4, supplementary Table S8,
http://links.lww.com/QAD/A862). Option Bþ was less
cost-effective compared with Option B than in the main
analysis (ICERUS$ 4530 per DALYaverted). In the cost-
effectiveness analysis comparing four scenarios (Options
Bþ and B with either current standard of care, or ‘best-
case’ scenario), Option Bþ with current standard of care
was strongly dominated by Option B with ‘best-case’
scenario (supplementary Table S9, http://links.lww.
com/QAD/A862). However, we did not include the
possible additional costs of interventions that would be
needed to improve the access to ANC, rates of HIV
testing, and retention. In the sensitivity analysis with a low Copyright © 2016 Wolters Kluwer HHIV incidence rate, the risk of MTCT was even lower
(7.8 and 9.2% in Option Bþ and B, respectively, during
the second pregnancies), and the ICER was substantially
lower than in the main analysis (US$ 206 per DALY
averted; supplementary Table S8, http://links.lww.com/
QAD/A862).Discussion
This modelling study for Malawi showed that compared
with Option B, Option Bþ averts one additional vertical
infection of HIV per 200 HIV-infected pregnant women
if we consider both the first and second pregnancy. The
difference is largely explained by the higher proportion of
women on ART at the time of the second conception
(39%) with Option Bþ, compared with Option B (18%).
Implementing Option Bþ costs more than Option B
because of the greater need for ART, but the additional
costs required under Option Bþ are largely offset by the
decreased future health costs because of the averted
infections.
In Malawi, 682 000 children were estimated to be born in
2014 [29], of whom at least 50 000 to HIV-infected
mothers. If we conservatively assume that HIV-positive
women give birth to two to three children during the
time they are infected, about 20 000 HIV-infected
women are expected to have their first child after their
HIV seroconversion each year. We can, therefore, expect
Option Bþ to prevent about 100 additional vertical HIV
infections every year.
Malawi has a high fertility rate (5.5 births per woman)
[10], which is similar in HIV-infected women [30].ealth, Inc. All rights reserved.
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Fig. 4. Risk of mother-to-child transmission in the main analysis and a sensitivity analysis representing the ‘best-case’ scenario.
In the ‘best-case’ sensitivity analysis, we assumed that 99% of all women attend antenatal care (20% within the first trimester), 96%
of women attending ANC will be tested for HIV, and LTFU is reduced by 75% from the level of the main analysis. LTFU, loss to
follow-up.Women become pregnant soon after stopping breastfeed-
ing, and 38% of women do not access ANC services until
24 weeks of gestation [11]. The women tend to access
ANC only later when the pregnancy is already visible
[31]. The late enrolment into ANC in combination with
the high fertility rate reduces the effectiveness of Option
B because early vertical transmission is not prevented.
Several factors influence the women‘s decision on when
to seek antenatal care. Some women do not understand
the importance of ANC beyond the first visit [32,33].
Health programmes should involve communities by
disseminating information about the importance of early
ANC. Other studies reported that fear of witchcraft
[31,32], religion [34], education [31,34] and economic
security [31,32] are associated with access to ANC.
Educating and economically empowering women could
improve early access to ANC and utilization of health
services. However, we also showed that even if access to
ANC can be accelerated, Option Bþ performs better
than Option B. In this case, Option Bþ is however less
cost-effective.
Although the total costs of the implementation of Option
Bþ are clearly higher than those of Option B, Option Bþ
can improve survival and quality of life in the long term,
and reduce the costs of HIV care in the future, by
preventing new infections. Depending on the assump-
tions on the long-term survival and care of the infected
infants, the ICER of Option Bþ compared with Option
B ranged between less than US$ 500 and more than US$
1300 per DALY averted. If we assume that the life
expectancy is no more than 45 years, and that the annual
cost of treating an infected person is at least US$ 200, the
ICER is less than US$ 810 (three times the per-capita
gross domestic product of Malawi) [10], and Option Bþ
can be considered cost-effective [35]. In many sub-
Saharan African countries, US$ 1300 per DALY averted
would be below per-capita gross domestic product and Copyright © 2016 Wolters Kluwetherefore, very cost-effective. In settings, where the HIV
incidence is lower than in southern Africa, Option Bþ
could also be considerably more cost-effective, since the
number of acutely infected pregnant women is lower, and
most infected women can therefore benefit from the early
PMTCT. Previous studies have reported other benefits of
Option Bþ such as promotion of maternal health through
early uptake of ART [8,9]. Option Bþ will also prevent
sexual transmissions of HIV because the women remain
on ART after the breastfeeding period [36]. These
benefits were not considered in our study.
The high LTFU has raised concerns about the effective-
ness of Option Bþ. Currently, up to 24% of women who
initiate ARTas part of Option Bþ in high volume clinics
are lost to follow-up by 6 months after ART initiation
[15]. About 47% of pregnant women lost to follow-up
received antiretroviral drugs only once and never
returned for their subsequent appointment [28], indi-
cating that they never started ART. Our results showed
that improving retention during pregnancy and breast-
feeding could further reduce the risk of MTCT under
both PMTCT strategies. The difference in the number of
HIV infections between strategies remained relatively
stable across the sensitivity analyses assuming different
rates of LTFU. These analyses thus suggest that the
suboptimal retention among women who start life-long
ART only for PMTCT does not affect the comparative
effectiveness of Option Bþ. Reducing LTFU made
Option Bþ less cost-effective because of the greater need
for ART, but this does not account for the benefits that
better retention has for the women’s own health.
Few modelling studies have compared Option Bþ with
Option B from the point of view of PMTCT. An analysis
of the cost-effectiveness of Option Bþ in Kenya, Zambia,
South Africa and Vietnam found that Option Bþ
prevents more vertical transmissions than Option B [37].r Health, Inc. All rights reserved.
960 AIDS 2016, Vol 30 No 6The studies were based on a simple deterministic model
and did not consider the changing risk of MTCT during
pregnancy, delivery and breastfeeding. Other mathemat-
ical modelling studies have explored the benefits and
cost-effectiveness of Option Bþ [8,9], but these studies
have focused on the maternal outcomes, and ignored the
potential of Option Bþ to prevent additional vertical
transmissions of HIV. Fasawe et al. [8] found that Option
Bþ substantially improves the mothers’ survival in
Malawi, making it a cost-effective strategy. Ciaranello
et al. [9] found that the life expectancy of the mothers in
Zimbabwe is higher in Option Bþ than other PMTCT
strategies. A cost-effectiveness analysis based on that study
further supported the implementation of Option Bþ.
These studies were also conducted before empirical data
from routine Option Bþ programmes became available
to inform modelling studies.
Our study has several potential limitations. First, we did not
model the viral load trajectories explicitly and used time
since infection to determine the risk of HIV infection.
Second, the model focused only on prevention of new
vertical HIV infections. We did not model the effect of the
start–stop approach implemented in Option B on the
mother’s health, the potential adverse effects associated
with starting and stopping ART, or the effect of Option Bþ
on horizontal transmission. Third, we did not model
subsequent pregnancies beyond two. However, we would
expect that most women who were infected with HIV
during or before their first pregnancy would be receiving
ART for their own health at the time of the third
pregnancy. We also excluded women who were already on
ART or in a late stage of HIV infection at the first
pregnancy, but the cascade of PMTCT care for these
women does not differ between the PMTCT strategies,
and excluding them should not influence our results.
The cost-effectiveness analysis was based on approxi-
mations about the long-term cost-savings and benefits of
PMTCT. The true lifetime costs and loss of life among
newly infected infants depend on the future of HIV
treatment and care. In our main analysis, we assumed that
the life expectancy of treated HIV-infected children is
10 years less than that of uninfected children. This may be
overoptimistic based on the current situation of HIV
care in resource-limited settings, but realistic when we
take into account the likely improvements in the future.
The life expectancy assumption was tested in a sensitivity
analysis, where we found that the assumed life expectancy
did not importantly influence the cost-effectiveness of
Option Bþ compared with Option B.
In conclusion, our results support the implementing of
the Option Bþ strategy. Despite the higher costs, Option
Bþwill likely become a cost-effective strategy in the long
term. Although LTFU reduces the benefit of PMTCT,
the effectiveness of Option Bþ, compared with Option
B, did not depend on assumptions regarding retention. Copyright © 2016 Wolters Kluwer HOption Bþ should be considered the preferred strategy to
prevent MTCTof HIV in resource-limited settings with
high fertility rate.Acknowledgements
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